Background: Since 2004, adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX or FLOX) have been the standard of care for patients with resected colon cancer. Herein we examine the change of outcomes over a 10-year period in patients with stage III colon cancer who received this regimen. Patients and methods: Individual patient data from the ACCENT database was used to compare the outcomes in older (1998e2003) and newer (2004e2009) treatment eras for patients with stage III colon cancer who received adjuvant FOLFOX or FLOX. The outcomes were compared between the two groups by the multivariate Cox proportionalhazards model adjusting for age, sex, performance score, T stage, N stage, tumor sidedness, and histological grade. Results: A total of 6501 patients with stage III colon cancer who received adjuvant FOLFOX or FLOX in six randomized trials were included in the analysis. Patients enrolled in the new era group experienced statistically significant improvement in time to recurrence [3-year rate, 76.1% versus 73.0%; adjusted hazard ratio (HR adj ) ¼ 0.83 (95% CI, 0.74e0.92), P ¼ 0.0008], disease-free survival (DFS) [3-year rate, 74.7% versus 72.3%; HR adj ¼ 0.88 (0.79e0.98), P ¼ 0.024], survival after recurrence (SAR) [median time, 27.0 versus 17.7 months; HR adj ¼ 0.65 (0.57e0.74), P < 0.0001], and overall survival (OS) [5-year rate, 80.9% versus 75.7%; HR adj ¼ 0.78 (0.69e0.88), P < 0.0001]. The improved outcomes remained in patients diagnosed at 45 years of age or older, low-risk patients (T1e3 and N1), left colon, mismatch repair proficient (pMMR), BRAF, and KRAS wild-type tumors. Conclusion: Improved outcomes were observed in patients with stage III colon cancer enrolled in clinical trials who received adjuvant FOLFOX/FLOX therapy in 2004 or later compared with patients in the older era. Prolonged SAR calls for revalidation of 3-year DFS as the surrogate endpoint of OS in adjuvant clinical trials and reevaluation of optimal follow-up of OS to confirm the trial findings based on the DFS endpoints.
